On Thursday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $169.63 which represents a decrease of $-0.72 or -0.42% from the prior close of $170.35. The stock opened at $170 and touched a ...

Asking dollar volume for luxury houses totals $124 million, with most properties selling “at a pretty robust pace.” ...

Richard Nieva is a San Francisco-based senior writer who covers technology. He joined Forbes in 2022 and covers public companies and artificial intelligence. Previously, he wrote for BuzzFeed News ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $199.5 which represents a decrease of $-1.01 or -0.50% from the prior close of $200.51. The stock opened at $201.16 and touched a ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbbVie (ABBV – Research Report). The ...

AbbVie Inc. (NYSE:ABBV – Get Free Report)’s stock price shot up 0.1% during trading on Friday after Citigroup raised their price target on the stock from $215.00 to $226.00. Citigroup currently has a ...

Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...

In a report released yesterday, Louise Chen from Cantor Fitzgerald maintained a Buy rating on AbbVie (ABBV – Research Report), with a ...

AbbVie’s deal team is having a busy week. Days after inking a $1.4 billion buyout, the drugmaker has put up the same again in biobucks to secure options on multispecific T-cell engagers from ...

NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics ...